SANA in the 13F filings
Sana Biotechnology Inc · CUSIP 799566104
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 23 Jan 2026
- Managers listing it
- 23
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 1 listed it in both
- Shares listed
- 55,721,720
- combined, among listed positions
- Reported value
- $227m
- combined, at the quarter end
Among the 92 comparable managers: 13 buyers (opened or added shares) and 10 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -8,389,300.
Managers listing SANA in Q4 2025
23 of 23 holders
Largest increases and reductions, by shares
Increases
- Balyasny Asset Management LLCnew position · 1,679,130 shares now+1,679,130
- Two Sigma Investments LPexisting position · 1,579,705 shares now+969,577
- T. Rowe Price Associates Incexisting position · 766,487 shares now+620,370
- Jane Street Group LLCexisting position · 668,884 shares now+438,264
- Two Sigma Advisers LPnew position · 221,671 shares now+221,671
Reductions
- Citadel Advisors LLCexisting position · 13,541 shares now-6,538,436
- Baillie Gifford & Coexisting position · 6,609,065 shares now-4,827,438
- Millennium Management LLCexisting position · 623,242 shares now-996,758
- Renaissance Technologies LLCexisting position · 1,691,116 shares now-301,384
- Woodline Partners LPexisting position · 1,317,641 shares now-60,595
New positions and exits
New (7)
Exited (1)
- Walleye Capital LLCwas $274k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2021 | 4 | $398m | n.a. | n.a. |
| Q2 2021 | 3 | $259m | n.a. | n.a. |
| Q3 2021 | 4 | $297m | n.a. | n.a. |
| Q4 2021 | 4 | $206m | n.a. | n.a. |
| Q1 2022 | 3 | $106m | n.a. | n.a. |
| Q2 2022 | 3 | $80m | n.a. | n.a. |
| Q3 2022 | 3 | $74m | n.a. | n.a. |
| Q4 2022 | 3 | $46m | n.a. | n.a. |
| Q1 2023 | 3 | $38m | n.a. | n.a. |
| Q2 2023 | 3 | $76m | n.a. | n.a. |
| Q3 2023 | 3 | $47m | n.a. | n.a. |
| Q4 2023 | 3 | $50m | 1 | 1 |
| Q1 2024 | 4 | $171m | 4 | 0 |
| Q2 2024 | 3 | $91m | 0 | 2 |
| Q3 2024 | 3 | $68m | 1 | 1 |
| Q4 2024 | 2 | $26m | 0 | 1 |
| Q1 2025 | 2 | $26m | 0 | 1 |
| Q2 2025 | 1 | $27m | 0 | 2 |
| Q3 2025 | 1 | $41m | 1 | 0 |
| Q4 2025 | 1 | $27m | 13 | 10 |
| Q1 2026 | 1 | $19m | 9 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
SANA and GILD →SANA and AMGN →SANA and ARGX →Choose a stock to compare with SANA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own SANA, latest filings →Back to the 13F Explorer →